Development and validation of predictive models of early immune effector cell–associated hematotoxicityEmily C. Liang, Jordan Gauthier, Barbara S. Pender et al.|Blood Advances|2024Cited by 11
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow upAndrew J. Portuguese, Jordan Gauthier, Jennifer J. Huang et al.|Haematologica|2025Cited by 4
Phase 2 Trial of SC Versus IV Anakinra to Prevent CRS and Neurotoxicity in LBCL Patients Receiving Lisocabtagene Maraleucel: Final Analysis and Comparison to Historical ControlEmily C. Liang, Jordan Gauthier, Jennifer J. Huang et al.|Transplantation and Cellular Therapy|2025Cited by 0
High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipientsEmily C. Liang, Richard T. Maziarz, Smith Kungwankiattichai et al.|Blood|2025Cited by 0
Independent assessment of ALC thresholds currently in use to predict motor/neurocognitive toxicities (MNTs) after treatment with ciltacabtagene autoleucelYein Jeon, Jordan Gauthier, Xiancheng Wu et al.|Blood|2025Cited by 0